ARTICLE | Clinical News
Alphamab Oncology, 3DMed start Phase III for PD-L1 antibody in cholangiocarcinoma
October 26, 2018 7:26 PM UTC
Alphamab Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase III trial of KN035 plus gemcitabine and oxaliplatin to treat cholangiocarcinoma.
The open-label, Chinese trial will enroll about 390 patients. The trial's primary endpoint is overall survival (OS)...
BCIQ Target Profiles